Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity

Gastrointestinal Endoscopy Clinics of North America

Volumn 24, Issue 3, 2014, Pages 367-378

  Walsh, Alissa ^a   Palmer, Rebecca ^b   Travis, Simon ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Inflammatory bowel disease; Mucosal healing; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL (TOPIC); COLITIS; COLON PERFORATION; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE ACTIVITY SCORE; HEALING; HUMAN; INTESTINAL BLEEDING; MUCOSAL HEALING; PRIORITY JOURNAL; RECTOSCOPY; REMISSION; REVIEW; SIGMOIDOSCOPY; ULCERATIVE COLITIS; VISUAL ANALOG SCALE; COLITIS, ULCERATIVE; COLON; INTESTINE MUCOSA; PATHOLOGY; PHYSIOLOGY; REGENERATION; TREATMENT OUTCOME; WOUND HEALING;

COLITIS, ULCERATIVE; COLON; CROHN DISEASE; HUMANS; INTESTINAL MUCOSA; REGENERATION; TREATMENT OUTCOME; WOUND HEALING;

EID: 84903462965     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2014.03.005     Document Type: Review

References (45)

1. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. Areview of activity indices and efficacy end points for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122(2):512-530.
2. D'Haens G., Sandborn W.J., Feagan B.G., et al. Areview of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132(2):763-786.
3. Neurath M.F., Travis S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012, 61(11):1619-1635.
4. Dave M., Loftus E.V. Mucosal healing in inflammatory bowel disease - a true paradigm of success?. Gastroenterol Hepatol 2012, 8(1):29-38.
5. Walsh A.J., Ghosh A., Brain A.O., et al. Comparing disease activity indices in ulcerative colitis. JCrohns Colitis 2014, 8:318-325.
6. D'Haens G.R., Fedorak R., Lémann M., et al. End points for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis 2009, 15(10):1599-1604.
7. De Cruz P., Kamm M.A., Prideaux L., et al. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013, 19(2):429-444.
8. Frøslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133(2):412-422.
9. Ardizzone S., Maconi G., Russo A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55(1):47-53.
10. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63(3):433-442.
11. Schnitzler F., Fidder H., Ferrante M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15(9):1295-1301.
12. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141(4):1194-1201.
13. Rutter M.D., Saunders B.P., Wilkinson K.H., et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004, 53(12):1813-1816.
14. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126(2):451-459.
15. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142(5):1102-1111.e2.
16. De Cruz P., Bernardi M.P., Kamm M.A., et al. Postoperative recurrence of Crohn's disease: impact of endoscopic monitoring and treatment step-up. Colorectal Dis 2013, 15(2):187-197.
17. Schoepfer A.M., Vavricka S., Zahnd-straumann N., et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. JCrohns Colitis 2012, 6(4):412-418.
18. Riley S.A., Mani V., Goodman M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32(2):174-178.
19. Burger D.C., Thomas S.J., Walsh A.J., et al. Depth of remission may not predict outcome of UC over 2 years. Gut 2011, 60(Suppl 1):A133.
20. Peyrin-Biroulet L., Bressenot A., Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. Clin Gastroenterol Hepatol 2013, [Epub ahead of print].
21. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2(4947):1041-1048.
22. Truelove S.C., Richards W.C. Biopsy studies in ulcerative colitis. Br Med J 1956, 1(4979):1315-1318.
23. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964, 1:89-92.
24. Powell-Tuck J., Day D.W., Buckell N.A., et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982, 27(6):533-537.
25. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92(6):1894-1898.
26. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. NEngl J Med 1987, 317(26):1625-1629.
27. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298(6666):82-86.
28. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. NEngl J Med 2005, 352(24):2499-2507.
29. Naganuma M., Ichikawa H., Inoue N., et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. JGastroenterol 2010, 45(9):936-943.
30. Matts S.G. The value of rectal biopsy in the diagnosis of ulcerative colitis. QJ Med 1961, 30:393-407.
31. Travis S.P., Schnell D., Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS). Gut 2012, 61(4):535-542.
32. Travis S.P., Schnell D., Krzeski P., et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013, 145(5):987-995.
33. Travis S.P., Higgins P.D., Orchard T., et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011, 34(2):113-124.
34. D'Haens G., Feagan B., Colombel J.F., et al. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology 2012, 143(6):1461-1469.
35. Kamm M.A., Sandborn W.J., Gassull M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007, 132(1):66-75.
36. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEngl J Med 2005, 353(23):2462-2476.
37. Thia K.T., Loftus E.V., Pardi D.S., et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis 2011, 17(6):1257-1264.
38. Pola S., Feagan B.G., Fahmy M., et al. Observer agreement and construct validity in central endoscopic assessment of disease activity in ulcerative colitis. Gastroenterology 2013, 144(5):S-763.
39. Corte C.J., Fernandopulle A.N., Catuneanu A., et al. Correlation between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. Gastroenterology 2013, 144(5):S-102.
40. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30(7):983-989.
41. Daperno M., D'Haens G., Van Assche G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60(4):505-512.
42. Rutgeerts P., Geboes K., Vantrappen G., et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99(4):956-963.
43. Hébuterne X., Lémann M., Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013, 62(2):201-208.
44. Rutgeerts P., Geboes K., Vantrappen G., et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984, 25(6):665-672.
45. De Cruz P., Kamm M.A., Hamilton A.L., et al. Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study. Gastroenterology 2013, 144(5):S-164.